CRI Funded Scientists

Ruth Ganss, PhD, CLIP Investigator

Harry Perkins Institute of Medical Research (Australia)

Area of Research: All Cancers, Pancreatic Cancer

Tumor blood vessels are highly chaotic and act to form a barrier which prevents cancer-targeting immune cells from infiltrating into tumors. To that end, Dr. Ruth Ganss has developed and patented a new treatment called LIGHT-VTP therapy, which specifically targets the abnormal blood vessels present in solid cancers, restores vessel function, and enables immune cells to deeply infiltrate the cancer. Now, she’s seeking to expand LIGHT-VTP applications to more advanced and hard-to-treat cancers against which current immunotherapies are ineffective. This includes pancreatic adenocarcinoma, a cancer where blood vessels are compressed in a highly fibrous or desmoplastic environment with overall dismal patient prognosis.

Thus far, Ganss’ team has established sophisticated preclinical models and state-of-the-art imaging techniques to monitor the therapeutic effects of this new treatment approach by itself and in combination with immunotherapies. As part of her commitment to clinical translation, these preclinical studies will be complemented by analyses of matching samples from human pancreatic cancer and brain melanoma metastases. Overall, this research will introduce a necessary and innovative combination treatment approach that could potentially enable more patients to benefit from immunotherapy.

I'm making a future where many more cancer patients can benefit from immunotherapy. -Dr. Ruth Ganss, CRI Scientist

Projects and Grants

Improving Immunotherapy for Desmoplastic and Metastatic Cancers

Harry Perkins Institute of Medical Research (Australia) | All Cancers, Pancreatic Cancer | 2020

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.